Stock Analysis

Essbio Second Quarter 2024 Earnings: EPS: CL$1.00 (vs CL$0.22 in 2Q 2023)

SNSE:ESSBIO-C
Source: Shutterstock

Essbio (SNSE:ESSBIO-C) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CL$57.6b (up 1.9% from 2Q 2023).
  • Net income: CL$3.33b (down 43% from 2Q 2023).
  • Profit margin: 5.8% (down from 10% in 2Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: CL$1.00.
earnings-and-revenue-history
SNSE:ESSBIO-C Earnings and Revenue History September 13th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Essbio's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Essbio (including 1 which can't be ignored).

Valuation is complex, but we're here to simplify it.

Discover if Essbio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.